Central Nervous System News and Research

RSS

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

New research investigating neurological decline in a population of "super healthy" elderly subjects found that the decline in neurological function of the peripheral nervous system attributed to aging may be related to metabolic factors, such as blood sugar levels, even if these factors are within the normal range.

16 Apr 2010

Study: Atorvastatin may slow down MS progression

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Cegedim Dendrite announces global SaaS CRM agreement with UCB

Cegedim Dendrite, the world's leading provider of life-sciences specific Customer Relationship Solutions, has signed a global SaaS CRM agreement with biopharmaceutical company UCB.

15 Apr 2010

Tapeworm infections of brain increasing in Mexico and bordering southwestern states

Tapeworm infections of the brain, which can cause epileptic seizures, appear to be increasing in Mexico and bordering southwestern states, Loyola University Health System researchers report.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Scientists at Birmingham Children's Hospital and the Universities of Nottingham and Southampton have developed new guidelines that should help doctors to diagnose brain tumours in children more quickly.

15 Apr 2010

Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 Apr 2010

Physicians warn parents on dangers of prescription drug abuse among children

With reports of increased prescription drug overdoses in emergency departments, the nation's emergency physicians are issuing a strong warning to parents about the dangers of abusing prescription drugs, which are now the second most abused drugs, after marijuana. Hospital visits caused by accidental and unintentional prescription drug overdoses went up 37 percent between 1999 and 2006, according to new data released by the American Journal of Preventive Medicine.

13 Apr 2010

Lean mass may decline among Alzheimer's patients

Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.

13 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Investment report on Somaxon Pharmaceuticals

StockPreacher.com announces an investment report featuring Somaxon Pharmaceuticals, Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

First proton therapy center for New Jersey

Cancer survivors joined representatives from ProCure Treatment Centers, Inc., Princeton Radiation Oncology, and CentraState Healthcare System to break ground on the ProCure Proton Therapy Center in Somerset - the first proton therapy center to be built in the state, located 40 miles from downtown Manhattan.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Cryo-Cell International, Inc. today announced results of a study published this month in the cover article of Stem Cells and Development showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders.

5 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

Scientists identify potential new method for treating sleeping sickness

Scientists have identified a potential new approach to treat human African trypanosomiasis (HAT), commonly known as sleeping sickness, which afflicts "tens of thousands of people in sub-Saharan Africa" annually, IRIN reports. By targeting an enzyme the sleeping sickness parasite needs in order to survive, researchers say they can kill it without causing harm to the patient (4/1).

2 Apr 2010

Central Nervous System News and Research

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

Study: Atorvastatin may slow down MS progression

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Cegedim Dendrite announces global SaaS CRM agreement with UCB

Tapeworm infections of brain increasing in Mexico and bordering southwestern states

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Investment report on Rexahn Pharmaceuticals

Physicians warn parents on dangers of prescription drug abuse among children

Lean mass may decline among Alzheimer's patients

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Investment report on Somaxon Pharmaceuticals

First proton therapy center for New Jersey

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Scientists identify potential new method for treating sleeping sickness

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News